Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary

Claus Vogelmeier(German Center for Lung Research), Gerard J. Criner(Temple University), Fernando J. Martínez(NewYork–Presbyterian Hospital), Antonio Anzueto(The University of Texas at San Antonio Health Science Center), Peter J. Barnes(Imperial College London), Jean Bourbeau(McGill University Health Centre), Bartolomé R. Celli(Brigham and Women's Hospital), Rongchang Chen(First Affiliated Hospital of Guangzhou Medical University), Marc Decramer(KU Leuven), Leonardo M. Fabbri(University of Modena and Reggio Emilia), Peter Frith(Flinders University), David Halpin(Royal Devon and Exeter Hospital), María Victorina López Varela(University of Modena and Reggio Emilia), Masaharu Nishimura(Hokkaido University), Nicolás Roche(Université Paris Cité), Roberto Rodríguez-Roisin(Universitat de Barcelona), Don D. Sin(University of British Columbia), Dave Singh(University of British Columbia), Robert A. Stockley(NIHR Surgical Reconstruction and Microbiology Research Centre), Jørgen Vestbo(University of Manchester), Jadwiga A. Wedzicha(Imperial College London), Àlvar Agustí(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
American Journal of Respiratory and Critical Care Medicine
March 1, 2017
Cited by 3,241Open Access
Full Text

Abstract

This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 report focuses primarily on the revised and novel parts of the document. The most significant changes include: (1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (2) for each of the groups A to D, escalation strategies for pharmacologic treatments are proposed; (3) the concept of deescalation of therapy is introduced in the treatment assessment scheme; (4) nonpharmacologic therapies are comprehensively presented; and (5) the importance of comorbid conditions in managing chronic obstructive pulmonary disease is reviewed.


Related Papers

No related papers found

Powered by citation graph analysis